Kabra Drugs Intrinsic Value
Kabra Drugs (KABRADG) median intrinsic value is ₹38.16 from 8 valuation models (range ₹20–₹57), vs current price ₹19.08 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. See KABRADG price to book ratio to compare market price against book value per share.
KABRADG Valuation Methods Summary — DCF, Graham Number & P/E
Kabra Drugs intrinsic value across 8 models vs current price ₹19.08 — upside/downside and value range per method. Check Kabra Drugs market cap to track the company's total market size over time.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹57.24 | ₹45.79 - ₹68.69 | +200.0% | EPS: ₹3.20, Sector P/E: 22x |
| Book Value Method | asset | ₹25.00 | ₹22.50 - ₹27.50 | +31.0% | Book Value/Share: ₹12.50, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹38.16 | ₹34.34 - ₹41.98 | +100.0% | Revenue/Share: ₹55.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹37.50 | ₹33.75 - ₹41.25 | +96.5% | EBITDA: ₹9.00Cr, EV/EBITDA: 10x |
| PEG Ratio Method | growth | ₹20.48 | ₹18.43 - ₹22.53 | +7.3% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹51.60 | ₹46.44 - ₹56.76 | +170.4% | Revenue Growth: 15.0%, Adj P/E: 16.1x |
| ROE Based Valuation | profitability | ₹38.16 | ₹34.34 - ₹41.98 | +100.0% | ROE: 26.7%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹25.00 | ₹22.50 - ₹27.50 | +31.0% | EPS: ₹3.20, BVPS: ₹12.50 |
KABRADG Intrinsic Value vs Market Price — All Valuation Models
Kabra Drugs fair value range ₹20–₹57 vs current market price ₹19.08 across 8 valuation models. For current market price and key ratios, visit Kabra Drugs share price chart.
KABRADG Intrinsic Value Analysis — Undervalued or Overvalued?
Kabra Drugs median intrinsic value ₹38.16, current price ₹19.08 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.
What is the intrinsic value of KABRADG?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Kabra Drugs (KABRADG) is ₹38.16 (median value). With the current market price of ₹19.08, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹20.48 to ₹57.24, indicating ₹20.48 - ₹57.24.
Is KABRADG undervalued or overvalued?
Based on our multi-method analysis, Kabra Drugs (KABRADG) appears to be trading below calculated value by approximately 100.0%.
KABRADG Financial Health — Key Ratios vs Industry Benchmarks
Kabra Drugs financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 26.7% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 7.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.53x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
KABRADG Cash Flow Quality — Operating & Free Cash Flow
Kabra Drugs operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-5 Cr | ₹-5 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |